Prohost Letter #461
Preventing HIV Infection and Treating Primary Biliary Cholangitis
Gilead Sciences
Gilead Sciences’ (GILD) stock price has been paralyzed for more than three consecutive years.  The long paralysis of Gilead reminds us of Amgen Therapeutics whose stock price was paralyzed at $50 for more than 3 years. The stock rebounded and continued to outperform after we selected it in 2011

Recently, Gilead announced . . .